Journal Home
Search for

Volume 13, Issue 1, Pages 82-89 (January 2007)


View previous. 13 of 22 View next.

Double Unrelated Reduced-Intensity Umbilical Cord Blood Transplantation in Adults

Karen K. Ballen1Corresponding Author Informationemail address, Thomas R. Spitzer1, Beow Y. Yeap1, Steven McAfee1, Bimalangshu R. Dey1, Eyal Attar1, Richard Haspel2, Grace Kao3, Deborah Liney3, Edwin Alyea3, Stephanie Lee3, Corey Cutler3, Vincent Ho3, Robert Soiffer3, Joseph H. Antin3

Received 10 May 2006; accepted 29 August 2006.

Abstract 

Umbilical cord blood (UBC) stem cells are a useful stem cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated with high transplantation-related mortality (TRM). In most cases, mortality is due to infection related to slow engraftment and immunoincompetence. In this study, we used a reduced-intensity conditioning regimen of fludarabine, melphalan, and antithymocyte globulin followed by 2 partially matched UBC units. The UBC units were a 4/6 HLA match or better with each other and with the patient and achieved a minimum precryopreservation cell dose of 3.7 × 107 nucleated cells/kg. A total of 21 patients (median age, 49 years) were treated. The median time to an absolute neutrophil count > 0.5 × 109/L was 20 days, and the median time to an unsupported platelet count > 20 × 109/L was 41 days. Two patients experienced primary graft failure and underwent a second UBC transplantation. One patient had a late graft failure. Acute graft-versus-host disease (GVHD) grade II-IV occurred in 40% of patients. The 100-day TRM was 14%, and the 1-year disease-free survival was 67%. Mixed chimerism was associated with a higher risk of chronic GVHD. Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen.

1 Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

2 Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

3 Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts

Corresponding Author InformationCorrespondence and reprint requests: Karen K. Ballen, MD, Division of Hematology/Oncology, Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114.

PII: S1083-8791(06)00606-9

doi:10.1016/j.bbmt.2006.08.041


View previous. 13 of 22 View next.